Practical Guidance on New Immuno-Oncology Strategies for Renal Cell and Urothelial Carcinoma

Practical Guidance on New Immuno-Oncology Strategies for Renal Cell and Urothelial Carcinoma

Sunday, June 4, 2017 in Chicago, Illinois
Dinner -- Sheraton Grand Chicago, 6:30 PM CST
Chicago Ballrooms 9 & 10


Clinical Rationale for Immunotherapy Approaches for Advanced Urothelial and Renal Cell Carcinoma
Chair: Elizabeth R. Plimack, MD, MS

Clinical Development of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Faculty presenter and moderator: Elizabeth R. Plimack, MD, MS

Clinical Development of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
Faculty presenter and moderator: M. Dror Michaelson, MD

Integrating Immune Checkpoint Inhibitors Into the Clinic
Faculty presenter and moderator: Sumanta Kumar Pal, MD


Program Chair
Elizabeth Plimack, MD, MS

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

M. Dror Michaelson, MD

Clinical Director, Genitourinary Cancer Center
Associate Professor of Medicine
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Sumanta Kumar Pal, MD

Associate Clinical Professor
Genitourinary Oncology
Department of Medical Oncology and Experimental Therapeutics
City of Hope Comprehensive Cancer Center
Duarte, California


Goal Statement
The goal of this activity is to increase participants’ knowledge of immune checkpoint inhibitors and improve competence and performance in the safe and effective integration of these agents in the treatment of renal cell carcinoma and urothelial carcinoma.

Target Audience
This program is intended for physicians, nurses, and other healthcare providers who care for patients with renal cell carcinoma or bladder cancer.

Learning Objectives

  • Gain insight on the mechanism of action and rationale for using immune checkpoint inhibitors to treat patients with advanced bladder cancer and renal cell carcinoma
  • Evaluate the available data and recommendations in the NCCN Guidelines® on different checkpoint inhibitors to guide therapy decisions for patients with bladder cancer and renal cell carcinoma
  • Describe challenges faced by the multidisciplinary care teams when planning therapeutic strategies for patients with genitourinary cancers
  • Compare the current understanding on the benefits of monotherapy and combination checkpoint inhibitor therapies in the treatment of first-line, second-line, and subsequent lines of therapy for bladder cancer and renal cell carcinoma
  • Recognize response patterns specific to immunotherapies, including pseudoprogression and atypical response kinetics
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC.

NCCN is accredited by the ACCME to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 2.0 contact hours

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings. 

National Comprehensive Cancer Network (NCCN) recognizes that you are a lifelong learner who has chosen to engage in continuing education to identify or fill a gap in knowledge, skill, or performance. As part of NCCN’s duty to you as a learner, you have the right to expect that your continuing education experience with NCCN includes content that: 

  • Promotes improvements or quality in healthcare;
  • Is valid, reliable, and accurate; n Offers balanced presentations that are free of commercial bias for or against a product/service;
  • Is vetted through a process that resolves any conflicts of interests of planners, faculty, or authors;
  • Is driven and based on learning needs, not commercial interests;
  • Addresses the stated objectives or purpose; and
  • Is evaluated for its effectiveness in meeting the identified educational need.

A learning environment that:

  • Supports learners’ ability to meet their individual needs;
  • Respects and attends to any special needs of the learners;
  • Respects the diversity of groups of learners; and
  • Is free of promotional, commercial, and/or sales activities. 

Disclosure of:

  • Relevant financial relationships planners, faculty, and authors have with commercial interests related to the content of the activity and
  • Commercial support (funding or in-kind resources) of the activity